JAK2 and esophageal squamous cell carcinoma: This distinct kinase inhibition profile may contribute to its potent effects observed in our ESCC models, potentially offering a therapeutic advantage in tumors driven primarily by JAK2 hyperactivation or those with specific dependencies on FLT3 signaling.